Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Satya, Johnson, Douglas B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858629/
https://www.ncbi.nlm.nih.gov/pubmed/31730012
http://dx.doi.org/10.1186/s40425-019-0805-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858629/
https://www.ncbi.nlm.nih.gov/pubmed/31730012
http://dx.doi.org/10.1186/s40425-019-0805-8

Ejemplares similares